EGFL7 Secreted By Human Bone Mesenchymal Stem Cells Promotes Osteoblast Differentiation Partly Via Downregulation Of Notch1-Hes1 Signaling Pathway

Zhang, Weijun; Bai, Jinwu; Li, Lijun; Zhang, Ye; Hang, Kai; Wang, Yibo; Wang, Zhongxiang; Ye, Chenyi; Xue, Deting

doi:10.1007/s12015-022-10503-z

Cited by 2 publications

(1 citation statement)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results suggest that SerpinB2 siRNA can effectively promote fracture healing in vivo, making it a potent target for clinical management of fractures. Similarly, to understand the role of Epidermal growth factor-like domain protein-7 (EGFL7) in the bone fracture microenvironment, siRNA targeting EGFL7 was designed and delivered to hBMSCs, and simultaneously, recombinant human (rh) BMSCs were used to evaluate changes in osteogenic differentiation and proliferation of hBMSCs [57]. To determine whether Notch signaling rescues the downregulation of osteogenic differentiation by EGFL7 siRNA in hBMSCs, a γ-secretase inhibitor was used, which blocked Notch1 signaling.…”

Section: Small Interfering Rna Therapy For Fracture Healingmentioning

confidence: 99%

Implications of siRNA Therapy in Bone Health: Silencing Communicates

Singh,

Singh

et al. 2024

Biomedicines

View full text Add to dashboard Cite

The global statistics of bone disorders, skeletal defects, and fractures are frightening. Several therapeutic strategies are being used to fix them; however, RNAi-based siRNA therapy is starting to prove to be a promising approach for the prevention of bone disorders because of its advanced capabilities to deliver siRNA or siRNA drug conjugate to the target tissue. Despite its ‘bench-to-bedside’ usefulness and approval by food and drug administration for five siRNA-based therapeutic medicines: Patisiran, Vutrisiran, Inclisiran, Lumasiran, and Givosiran, its use for the other diseases still remains to be resolved. By correcting the complications and complexities involved in siRNA delivery for its sustained release, better absorption, and toxicity-free activity, siRNA therapy can be harnessed as an experimental tool for the prevention of complex and undruggable diseases with a personalized medicine approach. The present review summarizes the findings of notable research to address the implications of siRNA in bone health for the restoration of bone mass, recovery of bone loss, and recuperation of bone fractures.

show abstract

Section: Small Interfering Rna Therapy For Fracture Healingmentioning

confidence: 99%